MX2015016978A - Proteinas de union a antigeno neutralizantes de citomegalovirus. - Google Patents
Proteinas de union a antigeno neutralizantes de citomegalovirus.Info
- Publication number
- MX2015016978A MX2015016978A MX2015016978A MX2015016978A MX2015016978A MX 2015016978 A MX2015016978 A MX 2015016978A MX 2015016978 A MX2015016978 A MX 2015016978A MX 2015016978 A MX2015016978 A MX 2015016978A MX 2015016978 A MX2015016978 A MX 2015016978A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen binding
- binding proteins
- cmv
- neutralizing antigen
- cmv neutralizing
- Prior art date
Links
- 102000025171 antigen binding proteins Human genes 0.000 title abstract 4
- 108091000831 antigen binding proteins Proteins 0.000 title abstract 4
- 230000003472 neutralizing effect Effects 0.000 title 1
- 241000701022 Cytomegalovirus Species 0.000 abstract 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 abstract 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/089—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Abstract
La presente invención se dirige a proteínas de unión a antígeno incluyendo, pero no limitadas a, anticuerpos monoclonales y fragmentos de unión a antígeno de los mismos, que se unen específicamente a y preferiblemente neutralizan citomegalovirus (CMV) humano; también comprendidos por la invención son las proteínas de unión a antígeno que han sido humanizadas; las proteínas de unión a antígeno de la invención son útiles como un agente terapéutico para tratar y/o prevenir infecciones de CMV en un paciente en necesidad de las mismas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361833184P | 2013-06-10 | 2013-06-10 | |
PCT/US2014/041504 WO2014200898A2 (en) | 2013-06-10 | 2014-06-09 | Cmv neutralizing antigen binding proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015016978A true MX2015016978A (es) | 2016-04-25 |
Family
ID=52022906
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015016978A MX2015016978A (es) | 2013-06-10 | 2014-06-09 | Proteinas de union a antigeno neutralizantes de citomegalovirus. |
Country Status (11)
Country | Link |
---|---|
US (1) | US9868777B2 (es) |
EP (1) | EP3008087A4 (es) |
JP (1) | JP2016521711A (es) |
KR (1) | KR20160018527A (es) |
CN (1) | CN105579469A (es) |
AU (1) | AU2014278481A1 (es) |
BR (1) | BR112015030892A2 (es) |
CA (1) | CA2912913A1 (es) |
MX (1) | MX2015016978A (es) |
RU (1) | RU2015155601A (es) |
WO (1) | WO2014200898A2 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102129107B1 (ko) | 2015-03-06 | 2020-07-02 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 항-lilrb 항체 및 암의 검출 및 치료를 위한 이의 용도 |
WO2017004151A1 (en) * | 2015-06-29 | 2017-01-05 | Regents Of The University Of Minnesota | Anti-apobec3 antibodies and methods of making and using |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
IL261666B2 (en) | 2016-03-31 | 2024-09-01 | Ngm Biopharmaceuticals Inc | Related proteins and methods of using them |
CA3019588A1 (en) | 2016-04-20 | 2017-10-26 | Merck Sharp & Dohme Corp. | Cmv neutralizing antigen binding proteins |
EP3455251A4 (en) * | 2016-05-09 | 2020-04-22 | Icahn School of Medicine at Mount Sinai | WIDE NEUTRALIZING HUMAN ANTI-CYTOMEGALOVIRUS ANTIBODIES AND METHODS OF USE |
JP2018203632A (ja) * | 2017-05-30 | 2018-12-27 | 公益財団法人ヒューマンサイエンス振興財団 | モノクローナル抗体及び測定キット |
CA3067835A1 (en) * | 2017-06-22 | 2018-12-27 | Apexigen, Inc. | Anti-vista antibodies and methods of use |
CN111032689B (zh) | 2017-08-24 | 2024-02-27 | 凡恩世制药(北京)有限公司 | 抗爱帕琳肽抗体及其用途 |
WO2019148410A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1 antibodies |
US20220056124A1 (en) * | 2018-09-05 | 2022-02-24 | The Board Of Regents Of The University Of Texas System | Monoclonal antibodies against endotrophin and the use thereof |
US10666510B2 (en) | 2018-10-30 | 2020-05-26 | Bank Of America Corporation | Conserving computing resources during network parallel processing |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
CN118580343A (zh) * | 2022-10-21 | 2024-09-03 | 珠海泰诺麦博制药股份有限公司 | 抗人巨细胞病毒抗体及其用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6361779B1 (en) * | 1993-11-08 | 2002-03-26 | Aventis Pasteur Limited | Transferrin receptor genes |
US20100034822A1 (en) * | 2005-03-30 | 2010-02-11 | Vega Masignani | Haemophilus Influenzae Type B |
WO2007094423A1 (ja) * | 2006-02-15 | 2007-08-23 | Evec Incorporated | ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
EA201270662A1 (ru) * | 2009-12-23 | 2013-01-30 | 4-Антибоди Аг | Связывающие элементы для человеческого цитамегаловируса |
JO3274B1 (ar) * | 2009-12-24 | 2018-09-16 | Regeneron Pharma | أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري |
WO2011125015A2 (en) | 2010-04-05 | 2011-10-13 | Bar-Ilan University | Protease-activatable pore-forming polypeptides |
EA201390467A1 (ru) | 2010-09-29 | 2013-11-29 | Дженентек, Инк. | Композиции антител и способы применения |
AU2012255143A1 (en) * | 2011-05-19 | 2014-02-20 | The Regents Of The University Of Michigan | Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation |
US20130039974A1 (en) * | 2011-08-10 | 2013-02-14 | Donald W. Kufe | Anti-muc1 antibodies for cancer diagnostics |
TWI570240B (zh) | 2011-09-09 | 2017-02-11 | 默沙東公司 | 作為細胞巨大病毒疫苗之條件式複製cmv |
-
2014
- 2014-06-09 BR BR112015030892A patent/BR112015030892A2/pt not_active Application Discontinuation
- 2014-06-09 JP JP2016518059A patent/JP2016521711A/ja active Pending
- 2014-06-09 EP EP14810982.0A patent/EP3008087A4/en not_active Withdrawn
- 2014-06-09 US US14/897,374 patent/US9868777B2/en active Active
- 2014-06-09 WO PCT/US2014/041504 patent/WO2014200898A2/en active Application Filing
- 2014-06-09 CN CN201480042995.6A patent/CN105579469A/zh active Pending
- 2014-06-09 MX MX2015016978A patent/MX2015016978A/es unknown
- 2014-06-09 KR KR1020157034735A patent/KR20160018527A/ko not_active Application Discontinuation
- 2014-06-09 AU AU2014278481A patent/AU2014278481A1/en not_active Abandoned
- 2014-06-09 RU RU2015155601A patent/RU2015155601A/ru not_active Application Discontinuation
- 2014-06-09 CA CA2912913A patent/CA2912913A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2016521711A (ja) | 2016-07-25 |
AU2014278481A1 (en) | 2015-12-03 |
WO2014200898A3 (en) | 2015-04-09 |
US9868777B2 (en) | 2018-01-16 |
CA2912913A1 (en) | 2014-12-18 |
BR112015030892A2 (pt) | 2017-08-29 |
EP3008087A4 (en) | 2017-03-01 |
CN105579469A (zh) | 2016-05-11 |
US20160130327A1 (en) | 2016-05-12 |
WO2014200898A2 (en) | 2014-12-18 |
EP3008087A2 (en) | 2016-04-20 |
RU2015155601A (ru) | 2017-07-14 |
KR20160018527A (ko) | 2016-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015016978A (es) | Proteinas de union a antigeno neutralizantes de citomegalovirus. | |
MX2022004072A (es) | Anticuerpos de factor xi y metodos de uso. | |
EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
MD4716C1 (ro) | Anticorpi anti-LAG3 şi fragmente de legare a antigenului | |
EP4223874A3 (en) | Human anti-il-33 neutralizing monoclonal antibody | |
EA201690167A1 (ru) | Гуманизованные или химерные антитела к cd3 | |
MX341076B (es) | Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. | |
WO2013188870A3 (en) | IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME | |
MY184189A (en) | Methods of treating nail and scalp psoriasis | |
MX2020008122A (es) | Anticuerpos anti-pd-1. | |
EA201990895A1 (ru) | Антитела к о1 и варианты их применения | |
PH12015501360A1 (en) | Bmp-6 antibodies | |
MX2019009498A (es) | Anticuerpos mimeticos de fgf21 y usos de los mismos. | |
MX2015008534A (es) | COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS. | |
PH12015501632A1 (en) | Humanized anti-hmgbi antibody or antigen-binding fragment thereof | |
TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
MX2017011480A (es) | Anticuerpo de anti-esclerostina, fragmento de union a antigeno y uso medico del mismo. | |
MA40526A (fr) | Protéines de fixation antigénique fixant le cxcr3 | |
EP4218817A3 (en) | Methods for treating metabolic diseases by inhibiting myostatin activation | |
WO2014143739A3 (en) | Anti-alpha v beta 6 antibodies and uses thereof | |
MX2017003014A (es) | Anticuerpos anti-alfa v beta 5 humanizados y usos de estos. | |
PH12018501674A1 (en) | Anti-citrullinated hla polypeptide antibodies and uses thereof | |
MX2017001983A (es) | Agentes de union a proteina r-espondina 1 (rspo1) y usos de los mismos. | |
WO2014144616A3 (en) | Anti-alpha v beta 5 antibodies and uses thereof | |
WO2012112842A3 (en) | Compositions and methods for treating poliovirus |